Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01FUL
|
||||
| Former ID |
DIB012145
|
||||
| Drug Name |
Balapiravir
|
||||
| Synonyms |
Balapiravir hydrochloride; HCV NS5B polymerase inhibitor, Roche; R-1626; RO4588161-001; RNA polymerase inhibitor (HCV infection), Roche; RNA polymerase inhibitor (hepatitis C infection), Roche; R-1479 prodrug (HCV infection), Roche
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | HCV infection [ICD9: 070.4, 070.5, 070.70; ICD10:B17.1, B18.2] | Phase 1 | [1] | ||
| Company |
Roche
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H30N6O8
|
||||
| Canonical SMILES |
[C@@H]1([C@H]([C@@H](O[C@]1(N=[N+]=[N-])COC(=O)C(C)C)n1<br />c(=O)nc(cc1)N)OC(=O)C(C)C)OC(=O)C(C)C
|
||||
| CAS Number |
CAS 690270-29-2
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Hepatitis C virus NS5B polymerase | Target Info | Inhibitor | [2] | |
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01096576) A Study of Balapiravir in Patients With Dengue Virus Infection. U.S. National Institutes of Health. | ||||
| REF 2 | R-1626, a specific oral NS5B polymerase inhibitor of hepatitis C virus. IDrugs. 2008 Oct;11(10):738-49. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.